CARL LYON MILLWARD
Medical Practice at 39 Ave, San Mateo, CA
License number
California A55816
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
2
222 W 39Th Ave, San Mateo, CA 94403
141 Crescent Ave, Burlingame, CA 94010
141 Crescent Ave, Burlingame, CA 94010
Phone
(650) 573-2222
Professional information
Dr. Carl L Millward, San Mateo CA - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
San Mateo Office
222 W 39Th Ave, San Mateo 94403
(650) 573-2222 (Phone), (650) 369-3309 (Fax)
222 W 39Th Ave, San Mateo 94403
(650) 573-2222 (Phone)
222 W 39Th Ave, San Mateo 94403
(650) 573-2222 (Phone), (650) 369-3309 (Fax)
222 W 39Th Ave, San Mateo 94403
(650) 573-2222 (Phone)
Certifications:
Anatomic & Clinical Pathology, 1998
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
San Mateo Office
222 W 39Th Ave, San Mateo 94403
222 W 39Th Ave, San Mateo 94403
San Mateo Medical Center
222 West 39Th Ave, San Mateo 94403
222 W 39Th Ave, San Mateo 94403
222 W 39Th Ave, San Mateo 94403
San Mateo Medical Center
222 West 39Th Ave, San Mateo 94403
Education:
Medical School
Thomas Jefferson University
Graduated: 1993
Thomas Jefferson University
Graduated: 1993
Carl Lyon Millward, San Mateo CA
Specialties:
Pathologist
Address:
222 W 39Th Ave, San Mateo, CA 94403
Education:
Doctor of Medicine
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology)
Methods Of Predicting Cancer Risk Using Gene Expression In Premalignant Tissue
US Patent:
2010029, Nov 18, 2010
Filed:
Apr 6, 2010
Appl. No.:
12/755368
Inventors:
Wayne Cowens - Tiburon CA, US
Maureen T. Cronin - Los Altos CA, US
Carl L. Millward - Burlingame CA, US
Francois Collin - Berkeley CA, US
Michael Crager - Redwood City CA, US
Maureen T. Cronin - Los Altos CA, US
Carl L. Millward - Burlingame CA, US
Francois Collin - Berkeley CA, US
Michael Crager - Redwood City CA, US
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435 6, 435 721
Abstract:
The present disclosure provides methods for assessing a patient's cancer risk and/or recurrence risk, which methods comprise assaying, in a biological sample obtained from the gastrointestinal (GI) tract of the patient, an expression level of a risk gene. The present disclosure also provides methods involving a cancer risk/recurrence risk sequence, i.e. the V600E mutation of the BRAF gene, which is useful for assessing cancer risk and/or recurrence risk in a patient.
Gene Expression Profile Algorithm And Test For Determining Prognosis Of Prostate Cancer
US Patent:
2013019, Aug 1, 2013
Filed:
Jan 28, 2013
Appl. No.:
13/752199
Inventors:
Mark Lee - Los Altos Hills CA, US
William Novotny - Menlo Park CA, US
Tara Maddala - Sunnyvale CA, US
Michael Crager - Menlo Park CA, US
Diana Cherbavaz - San Francisco CA, US
Robert J. Pelham - Belmont CA, US
Carl L. Millward - Burlingame CA, US
Dejan Knezevic - Palo Alto CA, US
William Novotny - Menlo Park CA, US
Tara Maddala - Sunnyvale CA, US
Michael Crager - Menlo Park CA, US
Diana Cherbavaz - San Francisco CA, US
Robert J. Pelham - Belmont CA, US
Carl L. Millward - Burlingame CA, US
Dejan Knezevic - Palo Alto CA, US
Assignee:
GENOMIC HEALTH, INC. - Redwood City CA
International Classification:
G06F 19/20, C12Q 1/68
US Classification:
435 611, 435 612, 702 19
Abstract:
The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.